Changes afoot at GSK; The first victim of IRA?; As work halts, families behind gene therapy seek control; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
The vaccine R&D revolution has gone global. How will the lessons from Covid-19 reshape the way we study, test, produce and distribute vaccines around the world? Join me on Wednesday for a panel discussion. You can sign up at no cost here.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.